PulseAugur
EN
LIVE 21:43:13
ENTITY BPC-157

BPC-157

PulseAugur coverage of BPC-157 — every cluster mentioning BPC-157 across labs, papers, and developer communities, ranked by signal.

Show in brief
Total · 30d
0
8 over 90d
Releases · 30d
0
0 over 90d
Papers · 30d
0
0 over 90d
TIER MIX · 90D
TOPICS
RELATIONSHIPS
RECENT · PAGE 1/1 · 8 TOTAL
  1. RESEARCH · CL_191665 ·

    FDA faces decision on popular peptides amid safety and efficacy concerns

    The FDA is facing a critical decision regarding the authorization of six popular but experimental peptides, which are increasingly being used for health, fitness, and longevity despite limited scientific evidence. Onlin…

  2. RESEARCH · CL_177491 ·

    FDA panel clashes with scientists over loosening peptide drug rules

    An FDA advisory panel has recommended loosening restrictions on the compounding of six out of seven peptides, despite concerns raised by agency scientists regarding their safety and efficacy. The panel, which included m…

  3. RESEARCH · CL_162255 ·

    FDA advisers back peptides despite safety concerns · 1 source tracked

    A panel advising the U.S. Food and Drug Administration has narrowly recommended easing restrictions on several peptides, including BPC-157 and TB-500, which are popular among wellness influencers and celebrities. Despit…

  4. RESEARCH · CL_157201 ·

    FDA panel to review peptides, potentially opening $3B market

    A Food and Drug Administration (FDA) panel is set to review seven peptides, potentially paving the way for their legal production and sale. The current market for these unproven substances operates in a regulatory gray …

  5. RESEARCH · CL_155228 ·

    FDA reviews popular peptides amid safety and efficacy concerns · 2 sources tracked

    The U.S. Food and Drug Administration (FDA) is set to review seven peptides for potential approval for compounding by pharmacies. These peptides, including BPC-157, TB-500, and Semax, are popular in longevity and wellne…

  6. RESEARCH · CL_152600 ·

    FDA peptide vote could unlock new telehealth market, mirroring Ozempic boom

    The FDA's upcoming vote on seven peptides, including BPC-157 and TB-500, could legitimize a new multibillion-dollar market for wellness injectables. Telehealth companies like Hims & Hers, which previously profited from …

  7. COMMENTARY · CL_89376 ·

    US sees surge in unapproved peptide use, driven by influencers

    A growing trend in the United States involves individuals self-administering unapproved peptides, often promoted by wellness influencers and podcasters rather than medical professionals. This phenomenon highlights a dec…

  8. COMMENTARY · CL_71840 ·

    Longevity influencers challenge medical expertise with unregulated peptide advice

    Social media influencers are increasingly disseminating information about longevity medicine, including complex peptide treatments, to large audiences. This trend bypasses traditional medical expertise, as patients ofte…